• news.cision.com/
  • Let'em know AB/
  • Cellevate launches Cellevat3d[®] nanofiber-based cell culture systems designed for faster bioprocessing, more efficient scale up and more than three times the viral vector yield
Svenska

Cellevate launches Cellevat3d[®] nanofiber-based cell culture systems designed for faster bioprocessing, more efficient scale up and more than three times the viral vector yield

Report this content

LUND, Sweden, November 4, 2024 – Cellevate is excited to announce its commercial launch of the world’s first nanofiber-based cell culture systems for viral vector production. The official global launch of Cellevat3d® nanofiber-based cell culture systems will take place at BIO-Europe in Stockholm, Sweden, on November 4-6, 2024. Join our launch event and company presentation on November 5 at 13:45 in Room K12 and visit us at booth #138.

Cellevat3d® nanofiber-based cell culture systems represent a potential paradigm shift in upstream bioprocessing, with up to 60 times larger surface area for cell growth than current solutions. The nanofibers create a true three-dimensional cell culture environment, significantly increasing cell densities, viral vector yields and productivity in stirred tank bioreactors. Furthermore, Cellevat3d® nanofiber cell culture systems are easy to use and easy to scale from lab to large scale bioreactors.

 “The launch and commercialization of Cellevate´s first industrial product, Cellevat3d® nanofiber-based cell culture systems, represent a fantastic milestone for the company and an amazing achievement for the Cellevate team. In less than three years we have developed, validated, produced, and are now starting to commercialize this breakthrough innovation in viral vector production. By implementing this completely new category of sustainable cell culture systems in process development, benchmarking data show that we can achieve more than three times the viral vector yield, faster and more efficient scale-up in bioreactors, and a decrease in production costs. Our mission is to accelerate the biomanufacturing revolution to make cell and gene therapies and novel vaccines more accessible to patients,” said Laura Chirica, CEO, Cellevate

For more information about our innovative Cellevat3d® nanofiber-based cell culture systems, to place an order or to connect with Cellevate representatives, please visit Cellevate’s updated website.

For more information, please contact:

Laura Chirica, PhD

CEO Cellevate

Email: laura.chirica@cellevate.com

About Cellevate

Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture systems for cell- and gene therapy and novel vaccines biomanufacturing. The core nanotechnology, Cellevat3d® is a sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased productivity and process economy. Cellevat3d® nanofiber-based products are designed as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale batch production.
 

For more information, please visit Cellevate’s updated website.

Prenumerera

Media

Media

Snabbfakta

Cellevate lanserar sin första produkt, Cellevat3d®, ett nanofiberbaserat cellodlingssystem designad för snabbare bioprocessing, effektivare uppskalning och mer än tre gånger så stort viralt vektorsutbyte.
Twittra det här
Vd Laura Chirica kommenterar: "Detta är en fantastisk milstolpe för företaget och en fantastisk prestation av Cellevate-teamet. På mindre än tre år har vi utvecklat, validerat, producerat och börjar nu kommersialisera denna banbrytande innovation inom viral vektorproduktion. Genom att implementera denna helt nya kategori av hållbara cellodlingssystem i processutveckling visar våra jämförelser att vi kan uppnå mer än tre gånger så mycket viralt vektorutbyte, snabbare och effektivare uppskalning i bioreaktorer och en minskning av produktionskostnaderna. Vårt uppdrag är att påskynda bioprocessing-revolutionen för att göra cell- och genterapier och nya vacciner mer tillgängliga för patienter.”
Twittra det här

Citat

The launch and commercialization of Cellevate´s first industrial product, Cellevat3d® nanofiber-based cell culture systems, represent a fantastic milestone for the company and an amazing achievement for the Cellevate team. In less than three years we have developed, validated, produced, and are now starting to commercialize this breakthrough innovation in viral vector production. By implementing this completely new category of sustainable cell culture systems in process development, benchmarking data show that we can achieve more than three times the viral vector yield, faster and more efficient scale-up in bioreactors, and a decrease in production costs. Our mission is to accelerate the biomanufacturing revolution to make cell and gene therapies and novel vaccines more accessible to patients.
Laura Chirica, CEO, Cellevate